# EDGAR Filing Document

**Accession Number:** 0001746473
**File Stem:** 0001746473-26-000024
**Filing Date:** 2026-3
**Character Count:** 16440
**Document Hash:** f757174da20c8266f57adaace92b8252
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001746473-26-000024.hdr.sgml**: 20260303

**ACCESSION NUMBER**: 0001746473-26-000024

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260303

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Material Modifications to Rights of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260303

**DATE AS OF CHANGE**: 20260303

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PLIANT THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001746473
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 474272481
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39303
- **FILM NUMBER:** 26715201

**BUSINESS ADDRESS:**
- **STREET 1:** 331 OYSTER POINT BOULEVARD
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 650-481-6770

**MAIL ADDRESS:**
- **STREET 1:** 331 OYSTER POINT BOULEVARD
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

?xml version='1.0' encoding='ASCII'? plrx-20260303

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

__________________________________________

**FORM 8-K**

__________________________________________

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 3, 2026**

__________________________________________

**PLIANT THERAPEUTICS, INC.**

**(Exact name of Registrant as Specified in Its Charter)**

__________________________________________

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39303** | **47-4272481** |
| **(State or Other Jurisdiction**<br>**of Incorporation)** | **(Commission File Number)** | **(IRS Employer**<br>**Identification No.)** |
| **331 Oyster Point Blvd., South San Francisco, CA** | | **94080** |
| **(Address of Principal Executive Offices)** | | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code: (650) 481-6770**

**Not Applicable** 

**(Former Name or Former Address, if Changed Since Last Report)**

__________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.0001 per share | PLRX | The Nasdaq Stock Market LLC |
| Series A Junior Participating Preferred Purchase Rights | N/A | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01&nbsp;&nbsp;&nbsp;&nbsp;Entry into a Material Definitive Agreement.**

------

The information set forth in Item 3.03 of this Current Report is incorporated into this Item 1.01 by reference.

**Item 3.03 &nbsp;&nbsp;&nbsp;&nbsp;Material Modification to Rights of Security Holders.**

On March 3, 2026, Pliant Therapeutics, Inc. (the "Company") and Computershare Trust Company, N.A., as rights agent (the "Rights Agent"), entered into an Amendment to Stockholder Rights Agreement (the "Amendment"), amending the Stockholder Rights Agreement, dated as of March 12, 2025, between the Company and the Rights Agent (the "Rights Agreement").

The Amendment changes the final expiration time of the Rights (as defined in the Rights Agreement) from 5:00 p.m., New York City time on March 11, 2026 to 5:00 p.m., New York City time on March 11, 2027. The Rights may still be earlier redeemed, exchanged or terminated in accordance with the terms of the Rights Agreement.

The extension of the final expiration time under the Rights Agreement is intended to reduce the likelihood that any entity, person or group is able to gain control of the Company through open market accumulation without paying all stockholders an appropriate control premium or providing the Board sufficient opportunity to make informed judgments and take actions that are in the best interests of the Company and all stockholders. The Rights Agreement was not amended in response to any specific takeover offer, and it is not intended to interfere with any merger or other business combination approved by the Board.

This description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, which is filed as Exhibit 4.2 hereto and incorporated herein by reference.

**Item 9.01 &nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit**<br>**No.** | **Description** |
| <u>[4.1](https://www.sec.gov/Archives/edgar/data/1746473/000119312525053509/d860128dex41.htm)</u> | <u>[Stockholder Rights Agreement, dated as of March 12, 2025, by and between the Company and Computershare Trust Company, N.A., as rights agent (which includes the Form of Rights Certificate as Exhibit B thereto) (incorporated by reference to Exhibit 4.1 to the Company's Registration Statement on Form 8-A, filed with the Securities and Exchange Commission on March 13, 2025, File No. 001-39303)](https://www.sec.gov/Archives/edgar/data/1746473/000119312525053509/d860128dex41.htm)</u> |
| <u>[4.2](pliant-rightsagreementamen.htm)</u> | <u>[Amendment to Stockholder Rights Agreement, dated as of March 3, 2026, by and between the Company and Computershare Trust Company, N.A., as rights agent (filed herewith)](pliant-rightsagreementamen.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | PLIANT THERAPEUTICS, INC. | PLIANT THERAPEUTICS, INC. |
| Date: March 3, 2026 | By: | /s/ Keith Cummings |
|  |  | Keith Cummings, M.D., MBA |
|  |  | Chief Financial Officer |

---

## Exhibit 4.2

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

**AMENDMENT TO STOCKHOLDER RIGHTS AGREEMENT**

This AMENDMENT TO STOCKHOLDER RIGHTS AGREEMENT (this "***Amendment***") is made effective as of March 3, 2026. This Amendment is an amendment to that certain Stockholder Rights Agreement, dated as of March 12, 2025 (the "***Rights Agreement***"), by and between Pliant Therapeutics, Inc., a Delaware corporation (the "***Company***"), and Computershare Trust Company, N.A. (the "***Rights Agent***"). The Company and the Rights Agent are collectively referred to herein as the "***Parties***". Capitalized terms used and not otherwise defined herein have the meanings ascribed to them in the Rights Agreement.

**W I T N E S S E T H:**

**WHEREAS**, the Parties entered into the Rights Agreement on March 12, 2025;

**WHEREAS**, the Board of Directors (the "***Board***") of the Company has determined that it is in the best interests of the Company and its stockholders to amend the Rights Agreement to change the Final Expiration Time from the Close of Business on March 11, 2026 to the Close of Business on March 11, 2027;

**WHEREAS**, pursuant to Section 27 of the Rights Agreement, prior to the Stock Acquisition Date, the Company may from time to time and in its sole discretion, and the Rights Agent shall, if the Company so directs, make any changes to the Rights Agreement that the Company may deem necessary or desirable that do not materially adversely affect the interests of the holders of Rights (other than the Acquiring Person, any Related Person thereof or any transferee of any Acquiring Person or any Related Person thereof), provided that the Company has delivered to the Rights Agent a certificate from an authorized officer of the Company stating that the proposed amendment complies with the terms of the Rights Agreement;

**WHEREAS**, the Stock Acquisition Date has not occurred;

**WHEREAS**, the Company has delivered to the Rights Agent a certificate from an authorized officer of the Company that states that this Amendment complies with the terms of the Rights Agreement and has directed the Rights Agent to amend the Rights Agreement as set forth herein.

**NOW THEREFORE**, in consideration of the premises and the mutual agreements herein set forth, the Parties hereby agree as follows:

**Section 1.Amendment to Rights Agreement.**

(a)&nbsp;&nbsp;&nbsp;&nbsp;The text of clause (i) of Section 7(a) of the Rights Agreement is hereby deleted and replaced in its entirety with the following:

"the Close of Business on March 11, 2027 (the "***Final Expiration Time***"), unless prior to such date stockholder approval has been obtained to extend the term of the Rights,".

------

(b)&nbsp;&nbsp;&nbsp;&nbsp;In the first paragraph of the Form of Rights Certificate (Exhibit B to the Rights Agreement), at page B-1, the first sentence beginning with the words "NOT EXERCISABLE AFTER MARCH 11, 2026" is hereby deleted and replaced in its entirety with the following:

"NOT EXERCISABLE AFTER MARCH 11, 2027 OR EARLIER IF REDEEMED OR EXCHANGED BY THE COMPANY OR AN EARLIER "EXPIRATION TIME" (AS DEFINED IN THE RIGHTS AGREEMENT) OCCURS."

(c)&nbsp;&nbsp;&nbsp;&nbsp;In the Summary of Rights to Purchase Preferred Stock (Exhibit C to the Rights Agreement), at page C-3, under the heading "Expiration Time", the reference to "March 11, 2026" is hereby deleted and replaced with "March 11, 2027".

(d)&nbsp;&nbsp;&nbsp;&nbsp;The text of Section 26 of the Rights Agreement is hereby deleted and replaced in its entirety with the following:

"**Section 26.**&nbsp;&nbsp;&nbsp;&nbsp;**<u>Notices</u>.** Notices or demands authorized by this Agreement to be given or made by the Rights Agent or by the holder of any Rights Certificate to or on the Company shall be sufficiently given or made if in writing and sent by first-class or express United States mail, FedEx or United Parcel Service or any other nationally recognized courier service, postage prepaid (or by facsimile transmission or e-mail, if receipt is confirmed telephonically) addressed (until another address is filed in writing with the Rights Agent) as follows:

Pliant Therapeutics, Inc.

331 Oyster Point Blvd.

South San Francisco, CA 94080

Attention: Keith Cummings

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Financial Officer

Telephone: (650) 481-6770

E-mail: KCummings@pliantrx.com

with a copy (which shall not constitute notice) to:

Goodwin Procter LLP

601 Marshall Street

Redwood City, CA 94063

Attention: Sam Zucker

E-mail: szucker@goodwinlaw.com

and

Goodwin Procter LLP

620 Eighth Avenue

New York, NY 10018

Attention: Leonard Wood

------

E-mail: leonardwood@goodwinlaw.com

Subject to <u>Section 21</u>, any notice or demand authorized by this Agreement to be given or made by the Company or by the holder of any Rights Certificate to or on the Rights Agent shall be sufficiently given or made if in writing and sent by first-class or express United States mail, FedEx or United Parcel Service or any other nationally recognized courier service, postage prepaid (or by facsimile transmission or e-mail, if receipt is confirmed telephonically) addressed (until another address is filed in writing with the Company) as follows:

Computershare Trust Company, N.A.

150 Royall Street

Canton, MA 02021

Attention: Client Services

Facsimile: (781) 575-4210

with a copy (which shall not constitute notice) to:

Kelley Drye & Warren LLP

300 Atlantic Street

Suite 700

Stamford, CT 06901

Attention: Merrill Stone

Telephone: (203) 324-1400

E-mail: mstone@kelleydrye.com

Notices or demands authorized by this Agreement to be given or made by the Company or the Rights Agent to the holder of any Rights Certificate (or, if prior to the Distribution Time, to the holder of shares of Common Stock) shall be sufficiently given or made if in writing, sent by first-class or express United States mail, FedEx or United Parcel Service or any other nationally recognized courier service, postage prepaid, addressed to such holder at the address of such holder as shown on the registry books of the Company."

**Section 2.Remaining Terms; Controlling Agreement.** All other provisions of the Rights Agreement that are not expressly amended hereby shall continue in full force and effect. From and after the execution and delivery of this Amendment, any references to the Rights Agreement in the Rights Agreement and other agreements or instruments shall be deemed to refer to the Rights Agreement as amended pursuant to this Amendment. In the event of any conflict between the terms of this Amendment and the Rights Agreement, this Amendment shall control.

**Section 3.Severability.** If any term, provision, covenant or restriction of this Amendment is held by a court of competent jurisdiction or other authority to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Amendment shall remain in full force and effect and shall in no way be affected, impaired or invalidated; provided, however, that notwithstanding anything in this Amendment to the contrary, if any such term, provision, covenant or restriction is held by such court or authority to

------

be invalid, void or unenforceable and the Board determines in its good faith judgment that severing the invalid, void or unenforceable language from this Amendment would adversely affect the purpose or effect of this Amendment, the right of redemption set forth in Section 23 of the Rights Agreement shall be reinstated and shall not expire until the Close of Business on the tenth (10th) day following the date of such determination by the Board.

**Section 4.Governing Law.** This Amendment shall be deemed to be a contract made under the laws of the State of Delaware and for all purposes shall be governed by and construed in accordance with the laws of such State applicable to contracts made and to be performed entirely within such State.

**Section 5.Descriptive Headings.** Descriptive headings of the Sections of this Amendment are inserted for convenience only and shall not control or affect the meaning or construction of any of the provisions hereof.

**Section 6.Counterparts.** This Amendment may be executed in any number of counterparts and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same instrument. Delivery of an executed signature page of this Amendment by facsimile or other customary means of electronic transmission (e.g., "pdf") shall be as effective as delivery of a manually executed counterpart hereof.

*[Remainder of Page Left Intentionally Blank]*

------

IN WITNESS WHEREOF, the Parties have caused this Amendment to be duly executed as of the day and year first above written.

**PLIANT THERAPEUTICS, INC.**

By: <u>/s/ Keith Cummings</u>__

Name: Keith Cummings, M.D., MBA

Title: Chief Financial Officer

**COMPUTERSHARE TRUST COMPANY, N.A.**

By: <u>/s/ Ralph Stock</u>_____

Name: Ralph Stock

Title: Manager, Relationship Management

*[Signature Page to Amendment to Stockholder Rights Agreement]*